Answers are grounded in this paper and cite their sources.
Background The prescription of melatonin to children and adolescents has increased dramatically in Sweden during the last ten years. Melatonin is recommended for sleeping disorders in children and adolescents as a second line of treatment after non-pharmacological alternatives in national guidelines. In the present study we aimed to evaluate the prescription of melatonin in relation to age and overweight status. Methods The population-based BMI Epidemiology Study cohort has height and weight available from school health care records for school children in the city of Gothenburg, Sweden´s second largest city. Information on melatonin prescription was retrieved through linkage with the National Prescribed Drug Register for individuals in the cohort. We included the first prescription of melatonin for boys which also had a weight measurement not earlier than three months before, or later than six months after the dispensing date (n=1,554). We present data for maximum dose and maximum dose per kg body weight in relation to overweight status (including obesity) and age above or below nine years. Results The range of the maximum dose of melatonin was 1–20 mg for first prescriptions and 1–25 mg for iterated prescriptions. Similar maximum doses were prescribed to individuals with overweight or obesity as to individuals with normal weight, and to individuals below and above 9 years of age. The range of the maximum prescribed melatonin dose per kg body weight was 0.01–0.85 mg/kg for first prescriptions and 0.02–1.53 mg/kg for iterated prescriptions. Of note, age and weight only explained a marginal part of the variance in maximum dose and displayed an inverse association with the maximum dose per kg. As a result, individuals with overweight or obesity, or age above 9 years, received lower maximum dose per kg body weight, compared with individuals with normal weight or below 9 years of age. Conclusion Thus, the prescribed melatonin dose to individuals under 18 years of age is not primarily informed by body weight or age, resulting in substantial differences in prescribed dose per kg body weight across BMI and age distribution. There is a general lack of knowledge regarding medicines in children, but for the sub-population of children with obesity, this knowledge gap is even larger. Given the ongoing obesity epidemic, there is a huge need to learn more regarding drug disposition in children and youth with obesity and therefore, high-quality clinical studies add.
No takes yet. Share an insight, caveat, or question.
Kimland et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: